Literature DB >> 2831187

Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions.

A Lalazar1, K H Weisgraber, S C Rall, H Giladi, T L Innerarity, A Z Levanon, J K Boyles, B Amit, M Gorecki, R W Mahley.   

Abstract

Apolipoprotein (apo) E, an important protein involved in cholesterol transport in the plasma, binds with high specificity and high affinity to the apoB, E (low density lipoprotein) receptor. Several lines of evidence have indicated that key basic residues in the vicinity of residues 140-160 of apoE are important in mediating binding to the receptor. Furthermore, apoE variants exhibiting defective receptor binding are associated with the genetic lipid disorder type III hyperlipoproteinemia. To determine whether other basic amino acids in this region of apoE also affect receptor binding activity, site-specific mutagenesis of apoE in a bacterial expression system was undertaken. This system had been used successfully to produce apoE3 that was structurally and functionally equivalent to human plasma apoE3. Variants of apoE in which neutral amino acids were substituted for basic residues at positions 136, 140, 143, and 150 were produced. The variants all displayed defective binding; their activity ranged from 9 to 52% of normal (a range similar to that seen with naturally occurring variants of human apoE). In addition, to determine whether the conformation of this region is important for receptor binding, we designed variants in which proline was substituted for leucine 144 or alanine 152. Both variants were defective, exhibiting 13 and 27% of normal binding, respectively. In contrast, a double mutant in which arginine was substituted for serine 139 and alanine for leucine 149 displayed slightly enhanced receptor binding activity. These studies confirm that the middle of the apoE molecule is important in receptor binding and indicate that only certain amino acid substitutions in this region interfere with receptor binding activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831187

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity.

Authors:  M Tolar; J N Keller; S Chan; M P Mattson; M A Marques; K A Crutcher
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

2.  Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated.

Authors:  M Tolar; M A Marques; J A Harmony; K A Crutcher
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

3.  Characterization and isolation of a high-density-lipoprotein-binding protein from bovine corpus luteum plasma membrane.

Authors:  K Ferreri; K M Menon
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

4.  Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy.

Authors:  Yoshiro Miyahara; Shinsuke Nishimura; Maho Watanabe; Kenji Ito; Hitoshi Nakashima; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2011-11-11       Impact factor: 2.801

Review 5.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

6.  Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1.

Authors:  Jan K Jensen; Klavs Dolmer; Peter G W Gettins
Journal:  J Biol Chem       Date:  2009-05-13       Impact factor: 5.157

Review 7.  LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies.

Authors:  Anna P Lillis; Lauren B Van Duyn; Joanne E Murphy-Ullrich; Dudley K Strickland
Journal:  Physiol Rev       Date:  2008-07       Impact factor: 37.312

8.  O-glycosylation on cerebrospinal fluid and plasma apolipoprotein E differs in the lipid-binding domain.

Authors:  Sarah A Flowers; Oliver C Grant; Robert J Woods; G William Rebeck
Journal:  Glycobiology       Date:  2020-01-28       Impact factor: 4.313

9.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

10.  Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.

Authors:  A M van den Maagdenberg; W Weng; I H de Bruijn; P de Knijff; H Funke; A H Smelt; J A Gevers Leuven; F M van't Hooft; G Assmann; M H Hofker
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.